• Share
  • Email
  • Embed
  • Like
  • Save
  • Private Content
ReportsnReports - Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth
 

ReportsnReports - Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth

on

  • 1,044 views

GBI Research, the leading business intelligence provider, has released its latest research, “Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by ...

GBI Research, the leading business intelligence provider, has released its latest research, “Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth”, which provides insights into the global vaccines market, forecast until 2017. The report provides an in-depth analysis of five vaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A and hepatitis B. The report also examines the immunization schedules for the covered vaccines. In addition, the report also includes insights into the vaccines R&D pipeline.

Statistics

Views

Total Views
1,044
Views on SlideShare
1,044
Embed Views
0

Actions

Likes
0
Downloads
7
Comments
0

0 Embeds 0

No embeds

Accessibility

Upload Details

Uploaded via as Adobe PDF

Usage Rights

© All Rights Reserved

Report content

Flagged as inappropriate Flag as inappropriate
Flag as inappropriate

Select your reason for flagging this presentation as inappropriate.

Cancel
  • Full Name Full Name Comment goes here.
    Are you sure you want to
    Your message goes here
    Processing…
Post Comment
Edit your comment

    ReportsnReports - Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth ReportsnReports - Adult and Adolescent Vaccines Market to 2017 - Accelerated Development and Introduction Plans (ADIP) by GAVI Alliance to Drive Growth Document Transcript

    • Adult and Adolescent Vaccines Market to 2017 – Accelerated Development andIntroduction Plans (ADIP) by GAVI Alliance to Drive GrowthReportsnReports.com adds GBI Research Market Research Report “Adult and AdolescentVaccines Market to 2017 – Accelerated Development and Introduction Plans (ADIP) by GAVIAlliance to Drive Growth‟‟ to its store.GBI Research, the leading business intelligence provider, has released its latest research,“Adult and Adolescent Vaccines Market to 2017 – Accelerated Development and IntroductionPlans (ADIP) by GAVI Alliance to Drive Growth”, which provides insights into the globalvaccines market, forecast until 2017. The report provides an in-depth analysis of fivevaccines, which include pneumococcal, seasonal flu, human papillomavirus, hepatitis A andhepatitis B. The report also examines the immunization schedules for the covered vaccines.In addition, the report also includes insights into the vaccines R&D pipeline.The report is built using data and information sourced from proprietary databases, primaryand secondary research, and in-house analysis by GBI Research‟s team of industry experts.GBI Research‟s analysis shows that the overall global vaccines market was valued at $28billion in 2010. The market is expected to witness growth at a CAGR of 11.5% for theforecast period, and will reach $56.7 billion by 2017. The global market revenues areexpected to increase due to the introduction of new molecules which are currently in theregulatory filing stage, and those in the later stages of development. The toppharmaceutical companies in the vaccines market are GlaxoSmithKline, Sanofi, Pfizer,Novartis AG., Merck & Co. Inc, and SP-MSD. Approximately 88% of the market is coveredby these six companies.ScopeThe scope of this report includes -  Data and analysis on the global adult and adolescent vaccines market  Annualized market data for the adult and adolescent vaccines market from 2007 to 2017 for pneumococcal vaccines, human pappilomavirus vaccines, seasonal flu vaccines, hepatitis A vaccines and hepatitis B vaccines  Key drivers and restraints that have had a significant impact on the market
    •  The competitive landscape of the global vaccines market  Key M&A activities, licensing agreements and co-development deals that took place in the vaccines market between 2009 and 2011.Reasons to buyThe report will enhance your decision making capability. It will allow you to -  Align your product portfolio to the markets with high growth potential.  Develop market-entry and market expansion strategies by identifying the potential region and therapeutic segments poised for strong growth.  Devise a more tailored country strategy through the understanding of key drivers and barriers of the vaccines market.  Develop key strategic initiatives by understanding the key focus areas and leading companies.  Accelerate and strengthen your market position by identifying key companies for mergers, acquisitions and strategic partnerships.Table of Contents1 Table of Contents1 Table of Contents 31.1 List of Tables 71.2 List of Figures 92 Adult and Adolescent Vaccines Market to 2017: Introduction 112.1 Overview 112.2 GBI Research Report Guidance 123 Adult and Adolescent Vaccines Market to 2017: Market Overview 133.1 Vaccine Preventable Diseases 133.2 Vaccine Manufacturing Process 144 Adult and Adolescent Vaccines Market to 2017: Global Vaccines Market 154.1 Market Forecasts 154.2 Market Share by Diseases Sector 174.3 Market Share by Geography 184.4 Average Cost of Vaccination per Child 19
    • 4.5 Target Population 194.6 Immunization Coverage 224.7 Unmet Needs 244.8 Market Trends 254.8.1 Immunization Programs 254.8.2 Public Private Partnerships 254.8.3 Production Capacity 264.8.4 Reimbursements 264.9 Drivers 264.9.1 Growth will be Driven by Vaccines Targeting New Diseases 274.9.2 The Adult Vaccines Segment will Provide a Significant Boost to Growth of the Market274.9.3 Pediatric Combination Vaccines will Continue to Drive Growth 274.9.4 Availability of Vaccine Technologies That Help Increase Efficacy and Safety will DriveInnovation and Growth 274.9.5 Cancer and HIV/AIDS Vaccines Hold Significant Potential for the Future 274.10 Barriers 284.10.1 Limitations in Production Capacity Delay the Realization of Potential 284.10.2 High Initial Capital Investments and Technical Expertise Act as Entry Barriers 284.10.3 Lack of Harmonized Regulations Delays Vaccine Launch and Acceptance 285 Adult and Adolescent Vaccines Market to 2017: The US Vaccines Market 295.1 Market Overview 295.2 Market Forecasts 295.3 Cost of Vaccination per Child in the US 315.4 Immunization Schedule 325.5 Regulatory Framework 335.6 Vaccine Procurement 345.7 Vaccine Stockpiling 356 Adult and Adolescent Vaccines Market to 2017: European Vaccines Market 366.1 Market Overview 366.2 Market Forecasts 366.3 Average Cost of Vaccination per Child 386.4 Vaccine Stockpiling 386.5 The UK 39
    • 6.5.1 Immunization Schedule 396.5.2 Regulatory Framework 396.5.3 Vaccine Procurement 396.6 France 406.6.1 Immunization Schedule 406.6.2 Regulatory Framework 416.6.3 Vaccine Procurement 416.7 Germany 426.7.1 Immunization Schedule 426.7.2 Regulatory Framework 436.7.3 Vaccine Procurement 446.8 Italy 446.8.1 Immunization Schedule 446.8.2 Regulatory Framework 446.8.3 Vaccine Procurement 456.9 Spain 456.9.1 Immunization Schedule 456.9.2 Regulatory Framework 466.9.3 Vaccine Procurement 477 Adult and Adolescent Vaccines Market to 2017: Rest of the World VaccinesMarket 487.1 Market Overview 487.2 Market Forecasts 487.3 Average Cost of Vaccination per Child 497.4 Immunization Schedule 497.5 Regulatory Framework 497.6 Vaccine Procurement 497.7 Vaccine Stockpiling 508 Adult and Adolescent Vaccines Market to 2017: Pneumococcal Vaccines Market518.1 Market Overview 518.2 Market Forecasts 518.3 Average Cost of Vaccination 528.4 Target Population 53
    • 8.5 Immunization Coverage 548.6 Product Analysis 548.6.1 Prevnar 7 548.6.2 Prevnar 13 (pneumococcal 13-valent conjugate vaccine) 548.6.3 Pneumovax 23 558.6.4 Synflorix 568.7 Vaccine Pipeline Analysis 578.7.1 Phase lll 578.7.2 Phase ll 588.7.3 Phase l 588.7.4 Preclinical/Discovery 589 Adult and Adolescent Vaccines Market to 2017: Human Pappilomavirus VaccinesMarket 599.1 Market Overview 599.2 Market Forecasts 599.3 Average Cost of Vaccination 609.4 Target Population 619.5 Immunization Coverage 629.6 Product Analysis 629.6.1 Gardasil 629.6.2 Cervarix 639.7 Vaccine Pipeline Analysis 639.7.1 Phase lll 639.7.2 Phase ll 649.7.3 Phase l 659.7.4 Preclinical/Discovery 6610 Adult and Adolescent Vaccines Market to 2017: Seasonal Flu Vaccines Market6710.1 Market Overview 6710.2 Average Cost of Vaccination 7110.3 Target Population 7210.4 Immunization Coverage 7310.5 Product Analysis 7310.5.1 Fluzone 73
    • 10.5.2 Fluarix 7310.6 Vaccine Pipeline Analysis 7410.6.1 Regulatory Filed Products 7410.6.2 Phase lll 7410.6.3 Phase ll 7510.6.4 Phase l 7610.6.5 Preclinical/Discovery 7711 Adult and Adolescent Vaccines Market to 2017: Hepatitis A Vaccines Market 7911.1 Market Overview 7911.2 Market Forecasts 7911.3 Average Cost of Vaccination 8011.4 Target Population 8111.5 Product Analysis 8211.5.1 Twinrix 8211.5.2 Havrix 8311.5.3 Vaqta 8311.5.4 Ambirix 8411.5.5 Avaxim 8411.6 Vaccine Pipeline Analysis 8511.6.1 NDA Filed Molecules 8511.6.2 Phase lll 8511.6.3 Preclinical/Discovery 8512 Adult and Adolescent Vaccines Market to 2017: Hepatitis B Vaccines Market 8612.1 Market Overview 8612.2 Market Forecasts 8712.3 Average Cost of Vaccination 8812.4 Target Population 8912.5 Product Analysis 9012.5.1 Recombivax HB 9012.5.2 Engerix-B 9012.5.3 Twinrix 9112.5.4 Comvax 9112.6 Vaccine Pipeline Analysis 9112.6.1 Regulatory Filed Products 91
    • 12.6.2 Phase lll 9212.6.3 Phase ll 9312.6.4 Phase l 9312.6.5 Preclinical/Discovery 9413 Adult and Adolescent Vaccines Market to 2017: Competitive Landscape 9513.1 Overview 9513.2 Market Share Analysis 9614 Adult and Adolescent Vaccines Market to 2017: Strategic Consolidations 9814.1 Mergers & Acquisitions 9814.1.1 Overview 9814.1.2 Top Deals in M&A 9814.1.3 M&A by Indication 9914.1.4 M&A by Year 10014.1.5 M&A by Geography 10114.1.6 M&A by Value 10214.2 Licensing Agreements 10314.2.1 Overview 10314.2.2 Top Licensing Deals 10314.2.3 Licensing Deals by Indication 10414.2.4 Licensing Deals by Year 10514.2.5 Licensing Deals by Geography 10614.2.6 Licensing Deals by Value 10714.3 Co-Development Deals 10814.3.1 Overview 10814.3.2 Top Co-Development Deals 10814.3.3 Co-Development Deals by Indication 10914.3.4 Co-Development Deals by Year 11014.3.5 Co-Development Deals by Geography 11114.3.6 Co-Development Deals by Value 11215 Appendix 11315.1 Market Definitions 11315.2 Abbreviations 11315.3 Research Methodology 114
    • 15.4 Global Vaccines Market 11415.4.1 Coverage 11415.4.2 Sources of Coverage 11515.4.3 Methodology 11515.5 Geographical Landscape 11515.5.1 Coverage 11515.5.2 Sources of Coverage 11515.5.3 Methodology 11515.6 Market Characterization 11615.6.1 Coverage 11615.6.2 Sources of Coverage 11615.6.3 Methodology 11615.7 Competitive Landscape 11615.7.1 Coverage 11615.7.2 Sources of Coverage 11615.7.3 Methodology 11715.8 Pipeline Analysis 11715.8.1 Coverage 11715.8.2 Sources of Coverage 11715.8.3 Methodology 11715.9 Strategic Consolidations 11715.9.1 Coverage 11715.9.2 Sources of Coverage 11715.9.3 Methodology 11715.10 Contact Us 11715.11 Disclaimer 11815.12 Sources 1181.1 List of TablesTable 1: Adult and Adolescent Vaccines Market to 2017, Vaccine Preventable Disease, 201013Table 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-2017 15Table 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication(%), 2010 17Table 4: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population
    • („000), 2007-2017 20Table 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population(„000), 2007-2017 21Table 6: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage(%), 2007-2009 23Table 7: Adult and Adolescent Vaccines Market to 2017, Global, GAVI Achievements, 2008-2010 25Table 8: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-2017 29Table 9: Adult and Adolescent Vaccines Market to 2017, the US, Cost of Vaccination ($),2010 31Table 10: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-2017 37Table 11: Adult and Adolescent Vaccines Market to 2017, Europe, Average Cost ofVaccination ($), 2009 38Table 12: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues($bn), 2007-2017 48Table 13: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues($bn), 2007-2017 51Table 14: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, AnnualCost of Vaccination ($), 2007-2017 52Table 15: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, TargetPopulation („000), 2007-2017 53Table 16: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase lllMolecules, 2011 57Table 17: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase llMolecules, 2011 58Table 18: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Phase lMolecules, 2011 58Table 19: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccines, Preclinical/ Discovery Molecules, 2011 58Table 20: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn),2007-2017 59Table 21: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost ofVaccination ($), 2007-2017 60Table 22: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population
    • („000), 2007-2017 61Table 23: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Product Comparison,2007-2017 62Table 24: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase lll Molecules,2011 63Table 25: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase ll Molecules,2011 64Table 26: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Phase l Molecules,2011 65Table 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Preclinical /Discovery Molecules, 2011 66Table 28: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues($bn), 2007-2017 69Table 29: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Annual Costof Vaccination ($), 2007-2017 71Table 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, TargetPopulation („000), 2007-2017 72Table 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, RegulatoryFiled Molecules, 2011 74Table 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase lllMolecules, 2011 74Table 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase llMolecules, 2011 75Table 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Phase lMolecules, 2011 76Table 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccines, Preclinical /Discovery Molecules, 2011 77Table 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues($m), 2007-2017 79Table 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Costof Vaccination ($), 2007-2017 80Table 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, TargetPopulation (million), 2007-2017 81Table 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, NDA FiledMolecules, 2011 85Table 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Phase lll
    • Molecules, 2011 85Table 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccines, Preclinical /Discovery Molecules, 2011 85Table 42: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues($m), 2007-2017 87Table 43: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Costof Vaccination ($), 2007-2017 88Table 44: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, TargetPopulation (million), 2007-2017 89Table 45: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, RegulatoryFiled Molecules, 2011 91Table 46: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase lllMolecules, 2011 92Table 47: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase llMolecules, 2011 93Table 48: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Phase lMolecules, 2011 93Table 49: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccines, Preclinical /Discovery Molecules, 2011 94Table 50: Adult and Adolescent Vaccines Market to 2017, Global, Top Deals in M&A (%),2009-2011 98Table 51: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-2011 99Table 52: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011 100Table 53: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-2011 101Table 54: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011102Table 55: Adult and Adolescent Vaccines Market to 2017, Global, Top Licensing Deals ($m),2009-2011 103Table 56: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication (%),2009-2011 104Table 57: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%),2009-2011 105Table 58: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography(%), 2009-2011 106
    • Table 59: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%),2009-2011 107Table 60: Adult and Adolescent Vaccines Market to 2017, Global, Co-Development Deals,2009-2011 108Table 61: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals byIndication (%), 2009-2011 109Table 62: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year(%), 2009-2011 110Table 63: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals byGeography (%), 2009-2011 111Table 64: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value(%), 2009-2011 1121.2 List of FiguresFigure 1: Adult and Adolescent Vaccines Market to 2017, Global, Vaccine ManufacturingProcess, 2010 14Figure 2: Adult and Adolescent Vaccines Market to 2017, Global, Revenues ($bn), 2007-2017 15Figure 3: Adult and Adolescent Vaccines Market to 2017, Global, Market Share By Indication(%), 2010 17Figure 4: Adult and Adolescent Vaccines Market to 2017, Global, Market Share ByGeography (%), 2010 18Figure 5: Adult and Adolescent Vaccines Market to 2017, Global, Target Pediatric Population(„000), 2007-2017 19Figure 6: Adult and Adolescent Vaccines Market to 2017, Global, Target Adult Population(„000), 2007-2017 20Figure 7: Adult and Adolescent Vaccines Market to 2017, Global, Immunization Coverage(%), 2007-2009 22Figure 8: Adult and Adolescent Vaccines Market to 2017, Global, Unmet Need, 2010 24Figure 9: Adult and Adolescent Vaccines Market to 2017, Global, Drivers and Barriers, 2007-2017 26Figure 10: Adult and Adolescent Vaccines Market to 2017, the US, Revenues ($bn), 2007-2017 29Figure 11: Adult and Adolescent Vaccines Market to 2017, the US, Immunization Schedule,2010 32Figure 12: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Development and
    • Approval Process, 2010 33Figure 13: Adult and Adolescent Vaccines Market to 2017, the US, Vaccine Procurement,2010 34Figure 14: Adult and Adolescent Vaccines Market to 2017, Europe, Revenues ($bn), 2007-2017 36Figure 15: Adult and Adolescent Vaccines Market to 2017, the UK, Immunization Schedule,2010 39Figure 16: Adult and Adolescent Vaccines Market to 2017, France, Immunization Schedule,2010 40Figure 17: Adult and Adolescent Vaccines Market to 2017, France, Distribution of VaccineAdministration by Sector, 2010 41Figure 18: Adult and Adolescent Vaccines Market to 2017, Germany, ImmunizationSchedule, 2010 42Figure 19: Adult and Adolescent Vaccines Market to 2017, Germany, Distribution of VaccineAdministration by Sector, 2010 43Figure 20: Adult and Adolescent Vaccines Market to 2017, Italy, Immunization Schedule,2010 44Figure 21: Adult and Adolescent Vaccines Market to 2017, Spain, Immunization Schedule,2010 45Figure 22: Adult and Adolescent Vaccines Market to 2017, Spain, Distribution of VaccineAdministration by Sector, 2010 46Figure 23: Adult and Adolescent Vaccines Market to 2017, Rest of the World, Revenues($bn), 2007-2017 48Figure 24: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, Revenues($bn), 2007-2017 51Figure 25: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, AnnualCost of Vaccination ($), 2007-2017 52Figure 26: Adult and Adolescent Vaccines Market to 2017, Pneumococcal Vaccine, TargetPopulation („000), 2007-2017 53Figure 27: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Revenues ($bn),2007-2017 59Figure 28: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Annual Cost ofVaccination ($), 2007-2017 60Figure 29: Adult and Adolescent Vaccines Market to 2017, HPV Vaccine, Target Population(„000), 2007-2017 61Figure 30: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Number of
    • Doses Produced, 2000-2010 67Figure 31: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Sales byChannel (%), 2009 68Figure 32: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, VaccinesProduced by Manufacturer, 2009-2010 68Figure 33: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, Revenues($bn), 2007-2017 69Figure 34: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, AnnualCost of Vaccination ($), 2007-2017 71Figure 35: Adult and Adolescent Vaccines Market to 2017, Seasonal Flu Vaccine, TargetPopulation („000), 2007-2017 72Figure 36: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Revenues($m), 2007-2017 79Figure 37: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, Annual Costof Vaccination ($), 2007-2017 80Figure 38: Adult and Adolescent Vaccines Market to 2017, Hepatitis A Vaccine, TargetPopulation (million), 2007-2017 81Figure 39: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Revenues($m), 2007-2017 87Figure 40: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, Annual Costof Vaccination ($), 2007-2017 88Figure 41: Adult and Adolescent Vaccines Market to 2017, Hepatitis B Vaccine, TargetPopulation (million), 2007-2017 89Figure 42: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 200996Figure 43: Adult and Adolescent Vaccines Market to 2017, Market Share Analysis (%), 201097Figure 44: Adult and Adolescent Vaccines Market to 2017, Strategic Consolidations (%),2009-2011 98Figure 45: Adult and Adolescent Vaccines Market to 2017, M&A by Indication (%), 2009-2011 99Figure 46: Adult and Adolescent Vaccines Market to 2017, M&A by Year (%), 2009-2011100Figure 47: Adult and Adolescent Vaccines Market to 2017, M&A by Geography (%), 2009-2011 101Figure 48: Adult and Adolescent Vaccines Market to 2017, M&A by Value (%), 2009-2011
    • 102Figure 49: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Indication(%), 2009-2011 104Figure 50: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Year (%),2009-2011 105Figure 51: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Geography(%), 2009-2011 106Figure 52: Adult and Adolescent Vaccines Market to 2017, Licensing Deals by Value (%),2009-2011 107Figure 53: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals byIndication (%), 2009-2011 109Figure 54: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Year(%), 2009-2011 110Figure 55: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals byGeography (%), 2009-2011 111Figure 56: Adult and Adolescent Vaccines Market to 2017, Co-Development Deals by Value(%), 2009-2011 112Latest Market Research Reports:  Radiation Detection Materials Markets – 2011  Printed Battery Markets – 2011  Global MDI, TDI and Polyurethane Market by Type, Applications, Prices, Regulations Trends & Forecasts 2011-2016About Us:ReportsnReports is an online library of over 75,000 market research reports and in-depthmarket research studies & analysis of over 5000 micro markets. We provide 24/7 online andoffline support to our customers. Get in touch with us for your needs of market researchreports.Follow us on Twitter: http://twitter.com/marketsreportsOur Facebook Page: http://www.facebook.com/pages/ReportsnReports/191441427571689
    • Contact:Mr. Priyank7557 Rambler road,Suite 727, Dallas, TX 75231Tel: +1-888-989-8004 EXT 106E-mail: sales@reportsandreports.comhttp://www.reportsnreports.comVisit Our Market Research Blog